Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only a small fraction of the provided claims can be evaluated from the supplied label excerpts (Pregnancy/Fetal Toxicity). Several mechanistic and adverse-effect claims are not supported by the provided excerpts and multiple safety-relevant efficacy/side-effect statements cannot be verified against the supplied label text.
Category Scores
Accurate Statements
Entresto can cause fetal harm when administered to a pregnant woman.
Supported by label excerpts 5.1 and 8.1 (Risk Summary): “ENTRESTO can cause fetal harm when administered to a pregnant woman.”
Entresto exposure during the second and third trimesters can reduce fetal renal function and increase fetal and neonatal morbidity and death.
Supported by 5.1 and 8.1: use of renin-angiotensin system drugs during 2nd/3rd trimesters reduces fetal renal function and increases fetal/neonatal morbidity and death.
Unsupported Statements
Entresto (sacubitril/valsartan) was approved by the U.S. Food and Drug Administration (FDA) on July 7, 2015.
Approval date is not present in the supplied label excerpts.
Entresto is prescribed to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with symptomatic chronic heart failure with reduced ejection fraction.
Indication/usage language is not present in the supplied label excerpts.
Entresto combines a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (valsartan).
Mechanism classification (neprilysin inhibitor; angiotensin II receptor blocker) is not present in the supplied label excerpts.
Sacubitril increases the levels of natriuretic peptides.
Not present in the supplied label excerpts.
Increased natriuretic peptides help reduce strain on the heart.
Not present in the supplied label excerpts.
Increased natriuretic peptides lower blood pressure.
Not present in the supplied label excerpts.
Valsartan blocks the effects of angiotensin II.
Not present in the supplied label excerpts.
Angiotensin II narrows blood vessels.
Not present in the supplied label excerpts.
Angiotensin II increases blood pressure.
Not present in the supplied label excerpts.
Entresto is manufactured by Novartis.
Manufacturer information is not present in the supplied label excerpts.
Common side effects of Entresto include low blood pressure.
Adverse reaction frequency/‘common side effects’ is not present in the supplied label excerpts. (The excerpts mention hypotension in neonates after in utero exposure, but not as a general ‘common side effect’.)
Common side effects of Entresto include high potassium levels.
Adverse reaction frequency/‘common side effects’ is not present in the supplied label excerpts. (The excerpts mention hyperkalemia in neonates after in utero exposure, but not as a general ‘common side effect’.)
Common side effects of Entresto include dizziness.
Not present in the supplied label excerpts.
Common side effects of Entresto include cough.
Not present in the supplied label excerpts.
Common side effects of Entresto include kidney problems.
‘Common side effects’ and general kidney problems are not present in the supplied label excerpts.
Contradictions
Important Omissions
The provided AI claims do not mention key pregnancy safety monitoring and management described in the supplied label excerpts (e.g., performing serial ultrasound examinations and closely observing neonates for hypotension, oliguria, and hyperkalemia; support blood pressure/renal perfusion; exchange transfusions/dialysis may be required).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several efficacy and safety-related claims (indication and ‘common side effects’) are not supported by the supplied label excerpts. The only clearly label-supported content is fetal toxicity in pregnancy; absence of other label-supported details increases risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims (approval date, indication, mechanism, and common adverse effects) are not supported by the provided FDA label excerpts, making alignment unverifiable and potentially misleading.
Suggested Improvement
Restrict claims to statements explicitly contained in the provided prescribing information excerpts (e.g., fetal harm in pregnancy; trimester-related fetal renal injury; monitoring/management steps for pregnancy and neonates). Provide additional relevant label sections (Indications and Usage, Adverse Reactions, Contraindications, Warnings/Precautions, Mechanism of Action, and Dosage/Administration) before evaluating those claims.